UPMC Shadyside is a nationally ranked, 520-bed non-profit, tertiary, teaching hospital located in the Shadyside neighborhood of Pittsburgh, Pennsylvania. UPMC Shadyside is a part of the University of Pittsburgh Medical Center, and grouped in with the flagship UPMC Presbyterian.

There are 520 beds in UPMC Shadyside Hospital.

During the past decade, UPMC Shadyside Hospital conducted 120 clinical trials. In the 10-year time frame, 120 clinical trials started and 68 clinical trials were completed, i.e. on average, 56.7% percent of trials that started reached the finish line to date. In the past 5 years, 47 clinical trials started and 47 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UPMC Shadyside Hospital" #1 sponsor was "National Cancer Institute (NCI)" with 45 trials, followed by "Alliance for Clinical Trials in Oncology" with 15 trials sponsored, "University of Pittsburgh" with 15 trials sponsored, "SWOG Cancer Research Network" with 14 trials sponsored and "NRG Oncology" with 14 trials sponsored. Other sponsors include 76 different institutions and companies that sponsored additional 45 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UPMC Shadyside Hospital" #1 collaborator was "National Cancer Institute (NCI)" with 66 trials as a collaborator, "NRG Oncology" with 27 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 11 trials as a collaborator, "Canadian Cancer Trials Group" with 8 trials as a collaborator and "Radiation Therapy Oncology Group" with 4 trials as a collaborator. Other collaborators include 55 different institutions and companies that were collaborators in the rest 55 trials.

According to Clinical.Site data, the most researched conditions in "UPMC Shadyside Hospital" are "Recurrent Squamous Cell Lung Carcinoma" (8 trials), "Breast Cancer" (7 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (7 trials), "Stage II Breast Cancer" (6 trials) and "Stage IIIA Breast Cancer" (6 trials). Many other conditions were trialed in "UPMC Shadyside Hospital" in a lesser frequency.

Most popular intervention types in "UPMC Shadyside Hospital" are "Drug" (128 trials), "Other" (72 trials), "Radiation" (62 trials), "Procedure" (45 trials) and "Biological" (42 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (36 trials), "Quality-of-Life Assessment" (26 trials), "Cisplatin" (23 trials), "Carboplatin" (16 trials) and "Intensity-Modulated Radiation Therapy" (16 trials). Other intervention names were less common.

The vast majority of trials in "UPMC Shadyside Hospital" are 153 trials for "All" genders, 17 trials for "Female" genders and 12 trials for "Male" genders.

Currently, there are NaN active trials in "UPMC Shadyside Hospital". 1 are not yet recruiting, 41 are recruiting, 51 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 66 completed trials in UPMC Shadyside Hospital, 5 suspended trials, and 14 terminated clinical trials to date.

Out of the total trials that were conducted in UPMC Shadyside Hospital, 15 "Phase 1" clinical trials were conducted, 60 "Phase 2" clinical trials and 85 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 27 trials that are defined as “Not Applicable".